SOTYKTU JAK Inhibitor for Psoriasis Treatment

SOTYKTU (deucravacitinib) belongs to a class of medications known as Janus kinase (JAK) inhibitors. JAK inhibitors have demonstrated significant advancements in the treatment of various immune-mediated conditions, particularly psoriasis. SOTYKTU, as a JAK inhibitor, offers a targeted and effective approach for managing moderate-to-severe plaque psoriasis in adults. it is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.


JAK inhibitors like SOTYKTU target the Janus kinase pathway, a critical signaling pathway involved in immune system regulation. By inhibiting specific JAK enzymes, these medications modulate the immune response, mitigating the excessive inflammation characteristic of psoriasis. SOTYKTU, specifically inhibiting tyrosine kinase 2 (TYK2) within the JAK family, plays a pivotal role in suppressing the aberrant immune response associated with psoriasis.

SOTYKTU represents a significant advancement in psoriasis treatment, harnessing the potential of JAK inhibition to provide targeted relief for individuals with moderate-to-severe plaque psoriasis. As with any medication, it is essential to follow your dermatologist’s guidance, adhere to the prescribed dosage, and promptly communicate any concerns or side effects for optimal management of your condition.

Contact your SOMA Skin & Laser dermatologist to discuss your treatment options for psoriasis.

Back to all Posts